Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan den Broeder

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|August 25, 2025
Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort StudyEvy Ulijn, Nathan den Broeder, Karen Bevers, et al.
Rheumatology (Oxford, England)|February 12, 2024
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS studyCéleste J T van der Togt, Nathan den Broeder, Marleen S Boonstra, et al.
Rheumatology (Oxford, England)|October 2, 2021
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort studyCelia A J Michielsens, Nathan den Broeder, Michelle L M Mulder, et al.
Therapeutic Advances in Musculoskeletal Disease|December 19, 2022
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)Céleste J T van der Togt, Lise M Verhoef, Bart J F van den Bemt, et al.
The Lancet. Rheumatology|July 27, 2025
Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trialAmy C D Peeters, Celia A J Michielsens, Elien A M Mahler, et al.
RMD Open|June 25, 2025
Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental studyIlse van Es, Johanna E Vriezekolk, Nathan den Broeder, et al.
Rheumatology (Oxford, England)|February 11, 2020
Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosisBrigit E Kersten, Nathan den Broeder, Frank H J van den Hoogen, et al.
Rheumatology (Oxford, England)|August 24, 2022
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritisCéleste J T van der Togt, David F Ten Cate, Bart J F van den Bemt, et al.
Rheumatology (Oxford, England)|April 4, 2022
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritisCéleste J T van der Togt, David F Ten Cate, Nathan den Broeder, et al.
Rheumatology (Oxford, England)|October 20, 2019
Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosisBrigit E Kersten, Nathan den Broeder, Frank H J van den Hoogen, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|August 25, 2025
Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis : A Retrospective Cohort StudyEvy Ulijn, Nathan den Broeder, Karen Bevers, et al.
Rheumatology (Oxford, England)|February 12, 2024
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS studyCéleste J T van der Togt, Nathan den Broeder, Marleen S Boonstra, et al.
Rheumatology (Oxford, England)|October 2, 2021
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort studyCelia A J Michielsens, Nathan den Broeder, Michelle L M Mulder, et al.
Therapeutic Advances in Musculoskeletal Disease|December 19, 2022
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)Céleste J T van der Togt, Lise M Verhoef, Bart J F van den Bemt, et al.
The Lancet. Rheumatology|July 27, 2025
Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trialAmy C D Peeters, Celia A J Michielsens, Elien A M Mahler, et al.
RMD Open|June 25, 2025
Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental studyIlse van Es, Johanna E Vriezekolk, Nathan den Broeder, et al.
Rheumatology (Oxford, England)|February 11, 2020
Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosisBrigit E Kersten, Nathan den Broeder, Frank H J van den Hoogen, et al.
Rheumatology (Oxford, England)|August 24, 2022
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritisCéleste J T van der Togt, David F Ten Cate, Bart J F van den Bemt, et al.
Rheumatology (Oxford, England)|April 4, 2022
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritisCéleste J T van der Togt, David F Ten Cate, Nathan den Broeder, et al.
Rheumatology (Oxford, England)|October 20, 2019
Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosisBrigit E Kersten, Nathan den Broeder, Frank H J van den Hoogen, et al.
Pageof 6